SAN DIEGO--(BUSINESS WIRE)--Verogen, Inc., the world’s first sequencing company solely dedicated to forensic science, announced today that it will begin taking orders and shipping products in the Americas (including the U.S., Canada, Mexico, Central and South America) beginning February 22, 2018 and in EMEA (Europe, Middle East, Africa) and China beginning March 9, 2018.
Verogen is an independent company established in August 2017 to provide sequencing technology based on Illumina Inc. platforms for forensic genomics applications. Beginning February 22, 2018 in the Americas and March 9, 2018 in EMEA and China, Verogen will be the exclusive provider of Illumina products for forensic genomics applications including the MiSeq FGx™ and ForenSeq™ DNA Signature Prep Kit. Service and support will be shared by Verogen and Illumina through the first quarter of 2019, as the two companies work to complete the commercial transition.
“Verogen is honored and excited to assume responsibility for providing the full suite of next generation products to the forensic community,” said Kirk Malloy, Verogen CEO. “The last year has seen significant advances in the transition of Illumina’s massively parallel sequencing (MPS) technology from a visionary method to a validated tool for forensic science, and the creation of Verogen has helped accelerate that progression.”
Verogen will assume commercial responsibilities in the rest of the world throughout 2018.
About Verogen, Inc.
Verogen, Inc. is committed to public safety and justice for all. Headquartered in the San Diego area, we serve those who serve the truth using genetic tools. We develop, manufacture, and sell products and services with a singular focus on advancing science to help unlock the true potential of forensic genomics. For more information, visit www.verogen.com.
https://twitter.com/VerogenBio
https://www.facebook.com/VerogenBio/
https://www.linkedin.com/company/verogen
For Research, Forensic and Paternity Use Only. Not for use in diagnostic
procedures.
© 2018 Verogen, Inc. All rights reserved.
